According to a new report LAMEA Cardiac Biomarkers Testing Market, published by KBV research, the LAMEA Cardiac Biomarkers Testing Market would witness market growth of 12.4% CAGR during the forecast period (2019-2025).
The Brazil market dominated the LAMEA Myoglobin Market by Country in 2018, growing at a CAGR of 12.2 % during the forecast period. The Argentina market is expected to witness a CAGR of 13.9% during (2019 - 2025). Additionally, The UAE market is expected to witness a CAGR of 12.6% during (2019 - 2025).
The Laboratory Testing market dominated the Brazil Cardiac Biomarkers Testing Market by Location of Testing in 2018, growing at a CAGR of 10.1 % during the forecast period. The Point of Care Testing market is expected to witness highest CAGR of 13.6% during (2019 - 2025).
The Myocardial Infarction market dominated the UAE Cardiac Biomarkers Testing Market by Application in 2018, thereby, achieving a market value of $113.6 million by 2025, growing at a CAGR of 11.4 % during the forecast period. The Congestive Heart Failure market is expected to witness a CAGR of 12.9% during (2019 - 2025). Additionally, The Acute Coronary Syndrome market is expected to witness highest CAGR of 11.3% during (2019 - 2025).
Full Report: https://www.kbvresearch.com/lamea-cardiac-biomarkers-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
By Type
By Application
By Location of Testing
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
